Volume 5.01 | Jan 17

Prostate Cell News 5.01 January 17, 2014
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
 
TOP STORY
ERRa Augments HIF-1 Signaling by Directly Interacting with HIF-1a in Normoxic and Hypoxic Prostate Cancer Cells
Researchers showed that estrogen-related receptor alpha (ERRa) is oncogenic in prostate cancer and also a key hypoxic growth regulator. ERRa-overexpressing prostate cancer cells were more resistant to hypoxia and showed enhanced hypoxia-inducible factor 1 (HIF-1a) protein expression and HIF-1 signaling. [J Pathol] Abstract
ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays - FREE Sample Request
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Aberrant MicroRNA Expression Likely Controls RAS Oncogene Activation during Malignant Transformation of Human Prostate Epithelial and Stem Cells by Arsenic
Inorganic arsenic (As) malignantly transforms the RWPE-1 human prostate epithelial line to CAsE-PE cells, and a derivative normal stem cell (SC) line, WPE-stem to As-Cancer SC line. MicroRNAs are non-coding but exert negative control on expression by degradation or translational repression of target mRNAs. [Toxicol Sci] Abstract

Morphological Differences between Circulating Tumor Cells from Prostate Cancer Patients and Cultured Prostate Cancer Cells
Scientists developed a software tool to investigate the morphological properties of circulating tumor cell from patients with castrate resistant prostate cancer and cultured prostate cancer cells in order to establish whether the latter is an appropriate model for the former. [PLoS One] Full Article

Enhanced Shedding of Extracellular Vesicles from Amoeboid Prostate Cancer Cells: Potential Effects on the Tumor Microenvironment
Researchers examined the mechanism of release and potential biological functions of extracellular vesicles (EV) shed from DIAPH3-silenced and other prostate cancer cells. They observed that stimulation of LNCaP cells with the prostate stroma-derived growth factor heparin-binding EGF-like growth factor, combined with p38MAPK inhibition caused EV shedding, a process mediated by ERK1/2 hyperactivation. [Cancer Biol Ther] Abstract

Human Adipose-Derived Mesenchymal Stromal Cell Pigment Epithelium-Derived Factor Cytotherapy Modifies Genetic and Epigenetic Profiles of Prostate Cancer Cells
Researchers examined the influence of adipose-derived mesenchymal stromal cells (ASCs) on gene expression and epigenetic methylation profiles of prostate cancer cells as well as the impact of expressing a therapeutic gene on modifying the interaction between ASCs and prostate cancer cells. [Cytotherapy] Abstract

Upregulation of RASGRP3 Expression in Prostate Cancer Correlates with Aggressive Capabilities and Predicts Biochemical Recurrence after Radical Prostatectomy
Researchers investigated the expression of guanyl nucleotide-releasing protein for Ras 3 (RasGRP3) in the cell lines and tissues in BPH and prostate cancer, as well as its associations with cancer invasion and prognosis in prostate carcinomas. [Prostate Cancer Prostatic Dis] Full Article

MHY-449, a Novel Dihydrobenzofuro[4,5-b][1,8] Naphthyridin-6-One Derivative, Induces Apoptotic Cell Death through Modulation of Akt/FoxO1 and ERK Signaling in PC3 Human Prostate Cancer Cells
Scientists examined the growth inhibitory effect of MHY-449 on p53 wild-type LNCaP and p53-null PC3 prostate cancer cells. MHY-449 treatment in androgen-independent and p53-null PC3 cells resulted in inhibition of cell growth and induction of apoptosis in a concentration-dependent manner. [Int J Oncol] Abstract

TUSC3 Loss Alters the ER Stress Response and Accelerates Prostate Cancer Growth In Vivo
Scientists provide evidence that tumor suppressor candidate 3 (TUSC3) is part of the oligosaccharyltransferase complex and affects N-linked glycosylation in mammalian cells. Loss of TUSC3 expression in DU145 and PC3 prostate cancer cell lines leads to increased proliferation, migration and invasion as well as accelerated xenograft growth in a PTEN negative background. [Sci Rep] Full Article

CLINICAL RESEARCH

Phase I/II Trial of Orteronel (TAK-700) – An Investigational 17,20-Lyase Inhibitor – In Patients with Metastatic Castration-Resistant Prostate Cancer
Researchers conducted a Phase I/II study in men with progressive, chemotherapy-naïve, metastatic castration-resistant prostate cancer and serum testosterone < 50 ng/dl. [Clin Cancer Res] Abstract

Prostate Cancer Incidence in Males with Lynch Syndrome
The purpose of this study was to retrospectively examine prostate cancer incidence in the Lynch syndrome cohort at the Ohio State University in comparison with that in the general population. [Genet Med] Full Article

Helical Intensity-Modulated Radiotherapy of the Pelvic Lymph Nodes with Integrated Boost to the Prostate Bed – Initial Results of the PLATIN 3 Trial
While the benefit of an additional radiotherapy of the pelvic lymph nodes is still under debate, the PLATIN 3 prospective Phase II clinical trial was initiated to substantiate toxicity data on postoperative intensity-modulated radiotherapy of the pelvic lymph nodes and the prostate bed. [BMC Cancer] Full Article

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
 
REVIEWS
Insulin-Like Growth Factor Receptor-1 (IGF-IR) as a Target for Prostate Cancer Therapy
In this review, the authors will update the most recent preclinical and clinical studies of IGF-IR therapy for prostate cancer. They also discuss the challenges for IGF-IR targeted therapies to achieve clinical benefit for prostate cancer. [Cancer Metastasis Rev] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with AbbVie
Seattle Genetics, Inc. announced that it has further expanded its antibody-drug conjugate (ADC) collaboration with AbbVie. ADCs are monoclonal antibodies that are designed to selectively deliver cytotoxic agents to tumor cells, resulting in targeted cell death. [Seattle Genetics, Inc.] Press Release

Madison Vaccines Closes $8 Million Series A Financing
Madison Vaccines Incorporated (MVI) announced an initial close of an $8 million Series A financing. The proceeds will support ongoing development of MVI’s pipeline, including completion of an expanded Phase II clinical trial for MVI-816 in non-metastatic prostate cancer patients with rapidly rising PSA, before the need for surgical or chemical castration. [Madison Vaccines Incorporated] Press Release

From our sponsor:
Looking for ALDH+ cancer stem cells? Watch a video to see how ALDEFLUORTM can help.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Maximizing the Value of Imaging in Oncology Drug Development
March 12-13, 2014
London, United Kingdom

NEW Cell Line Development Asia 2014
May 20-23, 2014
Shanghai, China

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Molecular Mechanisms of Cancer Progression (University of South Alabama)

Postgraduate Position – Chemokine Receptor Induced Cell Migration (University of East Anglia)

Graduate Student Position – Epigenetics and Chromatin (University of Victoria)

Postdoctoral Fellow – Mechanism of Prostate Cancer Bone Metastasis (Georgia Regents University)

Postdoctoral Position – Prostate Cancer Research (Weill Cornell Medical College)

Postdoctoral Position – Stem Cells and Bioengineering (Queensland University of Technology/Translational Research Institute)

Postdoctoral Fellow – Molecular Mechanisms of Prostate Cancer (Northwestern University – Feinberg School of Medicine)

Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

Postdoctoral Position – Chemistry and Prostate Cancer Imaging (University of California San Francisco)

Postdoctoral Fellow – Mechanisms Promoting Castrate Resistant Prostate Cancer (Mount Sinai School of Medicine)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Prostate Cell News: Archives | Events | Contact Us